Explore why Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...